 Epoprostenol
"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 4 | 1 | 5 | | 1981 | 1 | 0 | 1 | | 1982 | 0 | 1 | 1 | | 1984 | 1 | 0 | 1 | | 1988 | 0 | 1 | 1 | | 1989 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Geenen IL, Molin DG, van den Akker NM, Jeukens F, Spronk HM, Schurink GW, Post MJ. Endothelial cells (ECs) for vascular tissue engineering: venous ECs are less thrombogenic than arterial ECs. J Tissue Eng Regen Med. 2015 May; 9(5):564-76.
-
Huang N, Ashrafpour H, Levine RH, Forrest CR, Neligan PC, Lipa JE, Pang CY. Vasorelaxation effect and mechanism of action of vascular endothelial growth factor-165 in isolated perfused human skin flaps. J Surg Res. 2012 Jan; 172(1):177-86.
-
Katz SL, Adatia I, Louca E, Leung K, Humpl T, Reyes JT, Coates AL. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. Pediatr Pulmonol. 2006 Jul; 41(7):666-73.
-
Ashrafpour H, Huang N, Neligan PC, Forrest CR, Addison PD, Moses MA, Levine RH, Pang CY. Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. . 2004 Mar; 286(3):H946-54.
-
Forrest CR, Pang CY, Zhong AG, Kreidstein ML. Efficacy of intravenous infusion of prostacyclin (PGI2) or prostaglandin E1 (PGE1) in augmentation of skin flap blood flow and viability in the pig. Prostaglandins. 1991 Jun; 41(6):537-58.
-
Rand ML, Gross PL, Jakowec DM, Packham MA, Mustard JF. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin. Thromb Haemost. 1989 Apr 25; 61(2):254-8.
-
Pieroni JP, Dray F, Pace-Asciak CR, McGiff JC. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit. J Pharmacol Exp Ther. 1988 Oct; 247(1):63-8.
-
Pace-Asciak CR, Domazet Z. 9-Hydroxyprostaglandin dehydrogenase in rat kidney cortex converts prostaglandin I2 into 15-keto-13,14-dihydro 6-ketoprostaglandin E1. Biochim Biophys Acta. 1984 Nov 14; 796(2):129-35.
-
Friedman WF, Printz MP, Skidgel RA, Benson LN, Zednikova M. Prostaglandins and the ductus arteriosus. Adv Prostaglandin Thromboxane Leukot Res. 1982; 10:277-302.
-
Pace-Asciak CR, Carrara MC, Levine L. PGI2 is not a circulating vasodepressor hormone. Prog Lipid Res. 1981; 20:113-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|